Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Stepped Care Cognitive Behavioral Therap...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Investigators are studying how combining a stepped-care mental health counseling program with an evidence-based exercise program can help Latina cancer survivors feel better mentally and physically. The goal is to improve stress, emotions, and physical activity during and after cancer treatment. In addition, investigators will examine the feasibility and acceptability of the intervention among Latina cancer survivors.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Stepped Care Mental Health Counseling — Counseling Sessions: Everyone will have one orientation session with a counselor to learn about the study. After that, based on their levels of anxiety and depression, they may get between 1 and 7 counseling sessions. Milder levels of depression and anxiety will receive fewer sessions. The counseling sessions can include a self-help guide, coping strategies, self-help tips, and a type of therapy called cognitive behavioral therapy (CBT), which is specially adapted for Latina cancer survivors. The counseling sessions will take place online via zoom.
  • Behavioral: Exercise Program — The exercise program consists of easy to moderate aerobic and resistance training and discussions about staying active. These sessions will take place in your home, on zoom, led by a qualified exercise professional, and may be held in a group with other Latina cancer survivors. They will receive exercise equipment to use during the study and keep after the study ends. Exercise sessions are once per week for about an hour, and the discussion sessions take place before or after three of these sessions, and last about 30-45 minutes. If they miss a session or want to review, they will have access to recorded videos.

Primary Outcomes

  • Feasibility and acceptability of LIFT intervention components (At the completion of the study of the individual's exercise and counseling program.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-01
Completion: 2027-05
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Colorado State University
Collaborators: University of Colorado, Denver
Principal Investigators:
  • Jessica Gonzalez-Voller, Ph.D (PRINCIPAL_INVESTIGATOR) - Colorado State University
  • Heather Leach, Ph.D (PRINCIPAL_INVESTIGATOR) - Colorado State University
Contact Information
Study Contact:
Jessica Gonzalez-Voller, Ph.D
970-491-6289
JESSICA.GONZALEZ2@COLOSTATE.EDU
Heather Leach, Ph.D
970-491-8951
Heather.Leach@colostate.edu
Jessica Gonzalez-Voller, PhD
(970)-491-6289
JESSICA.GONZALEZ2@COLOSTATE.EDU
Colorado State Univerisity
Interventions
  • Behavioral: Stepped Care Mental Health Counseling — Counseling Sessions: Everyone will have one orientation session with a counselor to learn about the study. After that, based on their levels of anxiety and depression, they may get between 1 and 7 counseling sessions. Milder levels of depression and anxiety will receive fewer sessions. The counseling sessions can include a self-help guide, coping strategies, self-help tips, and a type of therapy called cognitive behavioral therapy (CBT), which is specially adapted for Latina cancer survivors. The counseling sessions will take place online via zoom.
  • Behavioral: Exercise Program — The exercise program consists of easy to moderate aerobic and resistance training and discussions about staying active. These sessions will take place in your home, on zoom, led by a qualified exercise professional, and may be held in a group with other Latina cancer survivors. They will receive exercise equipment to use during the study and keep after the study ends. Exercise sessions are once per week for about an hour, and the discussion sessions take place before or after three of these sessions, and last about 30-45 minutes. If they miss a session or want to review, they will have access to recorded videos.
Study Locations (1 sites)
Colorado State Univerisity, Fort Collins, Colorado 80538 United States
Eligibility Criteria
Inclusion Criteria: 1) currently undergoing or within 6-months of completing primary cancer(s) (2) self-identify as Latina and female, (3) over the age of 18 years, (4) reside in Colorado, (4) have access to internet, and be (5) English or Spanish speaking. Exclusion Criteria: (1) metastatic disease, (2) known contraindications for exercise (e.g. existing CVD or metabolic disease, use of an assistive-walking device, severe ataxia, etc.), (3) part of a vulnerable population (pregnant, homeless, in prison, have auditory impairment), and (4) currently participating in mental health counseling with a licensed professional and/or a structured exercise program.

Caregiver Stress and Sleep Study

NCT05219955
Recruiting
Conditions Depressive Symptoms, Caregiver Burden
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research study is to better understand how stress, sleep and activity might impact caregivers' mood and brain health. This study includes a randomized experimental component where therapists will systematically deliver one of two evidence-based talk-therapy treatments. The aim is to evaluate effects on meaningful health-relevant measures including morning activation levels, depression symptoms, rumination, and aspects brain connectivity previously linked with depression. Participants will complete surveys about their caregiving experiences, health, and mood, undergo an MRI, and wear an actigraphy watch that measures activity levels throughout the day and when sleeping.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: Morning Action Plan Execution — Each day, participants are asked to track if they do the morning activity plan.
  • Behavioral: Activity Strategy-based Session with Therapist — Participants will meet weekly with a trained therapist to discuss their prescribed activity plan. If unsuccessful, at weekly follow-ups, participants are asked to refine their plan or make a new one. Each session lasts about 30-45 minutes.
  • Behavioral: Attention-based Session with Therapist — Participants will meet weekly with trained a therapist to talk about stressors they experience, providing an opportunity to voice and self-address their problems. In this control condition, therapists will not deliver any particular strategy except for active listening and referring to the educational materials
  • Behavioral: Advance sleep-wake time — Some participants will be asked to adjust their sleep schedule to accommodate morning activity engagement by introducing or altering mechanisms known promote early rising (i.e., light exposure, reward and processes, etc.)

Primary Outcomes

  • Change from baseline in rumination at 6-months (Baseline, continuously up to weekly for 6-weeks, and follow-up (6 months))
  • Change from baseline in depressive symptoms at 6-months (Baseline, continuously up to weekly for 6-weeks, and follow-up (6 months))
  • Change from baseline in anxiety symptoms at 6-months (Baseline, continuously up to weekly for 6-weeks, and follow-up (6 months))
  • Change in objective Morning Activation Deficits (MADs) over 1 week (Continuously for up to 1-week at baseline)
  • Change in self-report Morning Activation Deficits (MADs) at 6-months (Baseline, continuously up to weekly for 6-weeks, and follow-up (6 months))
  • Change in resting-state connectivity at 6-weeks (Baseline and 6-weeks)
  • Change in neurological response to rumination cues at 6 weeks (Baseline and 6-weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-07-15
Completion: 2027-06-30
Eligibility
Age: 55 Years and older
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pittsburgh
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Stephen F Smagula, PhD (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Sara Sellars, MA
412-246-5963
alberts3@upmc.edu
Sara Sellars, MA
412-246-5963
alberts3@upmc.edu
UPMC Western Behavioral Health
Stephen Smagula, PhD
UPMC Western Behavioral Health
Interventions
  • Behavioral: Morning Action Plan Execution — Each day, participants are asked to track if they do the morning activity plan.
  • Behavioral: Activity Strategy-based Session with Therapist — Participants will meet weekly with a trained therapist to discuss their prescribed activity plan. If unsuccessful, at weekly follow-ups, participants are asked to refine their plan or make a new one. Each session lasts about 30-45 minutes.
  • Behavioral: Attention-based Session with Therapist — Participants will meet weekly with trained a therapist to talk about stressors they experience, providing an opportunity to voice and self-address their problems. In this control condition, therapists will not deliver any particular strategy except for active listening and referring to the educational materials
  • Behavioral: Advance sleep-wake time — Some participants will be asked to adjust their sleep schedule to accommodate morning activity engagement by introducing or altering mechanisms known promote early rising (i.e., light exposure, reward and processes, etc.)
Study Locations (1 sites)
UPMC Western Behavioral Health, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion Criteria: * Age 55 years or older. * Provide at least 15 hours/week of unpaid care to a patient with a dementia diagnosis. * Reporting stress or strain delivering care * No or stable pharmacotherapy for depression * Meets screening definition for having morning activation difficulty or a definite morning type per the Composite Morningness Questionnaire (CMQ) Exclusion Criteria: * Unsafe or unable to undergo MRI * Active Cognitive Behavioral Therapy for mood or insomnia * Probable dementia diagnosis * Deadly illness or plans to leave the study area * Current active substance use disorder
Conditions Depression
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Major depressive disorder (MDD) is a mood disorder characterized primarily by low mood, diminished interest, and reduced energy. Traditional views considered depression a non-degenerative condition; however, recent epidemiological studies have revealed its significant association with impaired social functioning. Data indicate that 59.3% of patients with depression experience social dysfunction of varying severity \[1\], particularly manifesting as difficulties in social interaction and relationship maintenance \[2\]. Therefore, investigating the mechanisms underlying social dysfunction is of great importance for promoting functional recovery in MDD, and dysfunction within the social reward system may represent a core factor, though the specific neural mechanisms remain unclear. The ultimate goal of understanding the neural mechanisms underlying social reward impairment in depressed patients is to improve therapeutic outcomes. Temporal Interference (TI) stimulation, as a non-invasive deep brain stimulation technique, utilizes high-frequency current differentials to generate low-frequency amplitude-modulated electric fields, enabling precise targeting of deep brain regions. This study employs multimodal assessment methods-such as functional magnetic resonance imaging (fMRI), electroencephalography (EEG), and specific cognitive-behavioral tasks-combined with TI stimulation to observe immediate changes in functional connectivity, neural activity, and related cognitive functions (e.g., decision-making, memory) across participant groups. The research aims to elucidate the roles of the parahippocampal gyrus, orbitofrontal cortex, and striatum in social reward impairment in depression, and to explore circuit-based intervention targets, thereby providing novel strategies for the recovery of social functioning in MDD.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Temporal Interference Simulation(TIS) — the total stimulation duration was 20 minutes, including a 40-second current ramp-up at the beginning and a 40-second ramp-down at the end.
  • Device: Temporal Interference Stimulation(TIS) — Sham stimulation has only 40 seconds of current ramping-up and ramping-down at the beginning and end of the stimulation to simulate the sensation of actual stimulation.

Primary Outcomes

  • Change in Hamilton Depression Rating Scale (HAMD) Score (baseline and immediately after the intervention)
  • Change in The Positive and Negative Affect Schedule (PANAS) Score (Baseline and immediately after the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-15
Completion: 2026-07-10
Eligibility
Age: 16 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Mental Health Center
Contact Information
Study Contact:
daihui Peng, MD. PhD.
18017311136
pdhsh@126.com
Interventions
  • Device: Temporal Interference Simulation(TIS) — the total stimulation duration was 20 minutes, including a 40-second current ramp-up at the beginning and a 40-second ramp-down at the end.
  • Device: Temporal Interference Stimulation(TIS) — Sham stimulation has only 40 seconds of current ramping-up and ramping-down at the beginning and end of the stimulation to simulate the sensation of actual stimulation.
Study Locations (1 sites)
Shanghai Mental Health Center, Shanghai, China China
Eligibility Criteria
Inclusion Criteria: * 16-60 years old; * Meeting with the criteria of major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5; * Scored 20 or higher on the Hamilton's Depression Scale with 24 items (HAMD-24); * With enough audio-visual ability and comprehensive ability to accomplish the visits; * Be necessary and suitable to accept the treatment of antidepressants; * Scored less than 14 on Hamilton's Anxiety Scale (HAMA) and scored less than 14 on the Hypomania Symptom Checklist-32 (HCL-32); * With 2 or more atypical symptoms including significant weight gain or increase in appetite, hypersomnia, leaden paralysis, and a long-standing pattern of interpersonal rejection sensitivity that results in significant social or occupational impairment. Exclusion Criteria: * Severe medical or neurological problems; * Previous mania or hypomania episodes; * Female patients who are pregnant, planning to be pregnant or breastfeeding; * Actively suicide ascertained by research psychiatrist or 3rd item of HAMD scored≥3(suicidality); * Had ECT, MECT or rTMS in the past 6 months; * Experienced severe personality disorder, mental retardation, anorexia/ bulimia nervosa.
Conditions Pain Management, Thoracic Trauma, Pulmon...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter clinical trial conducted in Vinnytsia, Rivne, and Lviv, Ukraine, focusing on the management of acute pain following thoracic injuries sustained during combat. The main purpose of the study is to evaluate and compare the effectiveness and safety of two minimally invasive procedures, cryoablation and radiofrequency ablation, in controlling severe chest pain and improving patients' recovery. Cryoablation involves applying extreme cold to specific intercostal nerves to reduce pain signals, while radiofrequency ablation uses controlled heat to achieve a similar effect. Both procedures target the nerves responsible for transmitting pain from the injured areas and are performed by experienced clinicians under careful monitoring to minimize risks. Adult patients who have experienced thoracic combat trauma and are experiencing moderate to severe pain may be eligible to participate in the study if they are able to provide informed consent and comply with the study procedures. Participants will be randomly assigned to receive either cryoablation or radiofrequency ablation. Pain intensity will be assessed before the procedure, and then again at four, twenty-four, and seventy-two hours afterward using a standardized verbal numeric rating scale. In addition to measuring changes in pain, the study will monitor opioid medication use to determine whether either procedure reduces the need for pain-relieving drugs. Mechanical pain sensitivity will be evaluated using Von Frey testing, and pulmonary function will be assessed using incentive spirometry to determine whether pain reduction improves the ability to breathe deeply and cough effectively. The impact of pain on daily activities, quality of life, and emotional well-being will also be measured using validated tools such as the LANS scale, the McGill Pain Questionnaire, and the PHQ-9 depression screening questionnaire. The study aims to provide important information on the relative benefits and risks of cryoablation and radiofrequency ablation for the treatment of acute thoracic pain, including changes in pain intensity, opioid consumption, respiratory function, and overall comfort. Potential risks associated with the procedures include temporary soreness, bruising, or rare complications, but all interventions are performed under strict safety protocols. Participation in this study may allow patients to experience better pain control, potentially reduced reliance on opioid medications, and faster recovery, while contributing valuable data that could improve pain management strategies for other patients in similar circumstances. Data collected during the study will be analyzed to compare the effectiveness of the two procedures and to identify factors that may influence outcomes, such as age, body mass index, the number of intercostal levels treated, and baseline pain scores. The study provides a structured, evidence-based approach to understanding acute pain management after thoracic…

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Cryoablation — Cryoablation and radiofrequency ablation are minimally invasive interventional pain management techniques used in this study to target intercostal nerves involved in pain transmission following thoracic combat-related trauma. Cryoablation achieves analgesia through the localized application of extreme cold, producing a temporary and reversible interruption of nerve conduction while preserving nerve structure. In contrast, radiofrequency ablation uses controlled radiofrequency-generated thermal energy to modulate nerve function and reduce pain transmission. Both interventions are performed percutaneously under image guidance to ensure accurate targeting of the affected intercostal nerves, with the number of treated levels determined by injury pattern and clinical assessment. Each intervention is administered in addition to standard trauma and supportive care, with the aim of reducing acute pain intensity, limiting opioid requirements, and improving functional outcomes such as respirator
  • Procedure: Radiofrequency ablation alone — Radiofrequency ablation is a minimally invasive interventional technique that uses controlled radiofrequency-generated thermal energy to modulate peripheral nerve function and reduce pain transmission. In this study, radiofrequency ablation is applied to intercostal nerves associated with thoracic combat-related trauma using a percutaneous, image-guided approach. Thermal energy is delivered in a controlled manner to achieve nerve modulation while limiting damage to surrounding tissues. This intervention is intended to provide effective acute pain relief, reduce opioid requirements, and improve functional outcomes such as respiratory mechanics in patients with thoracic injuries.

Primary Outcomes

  • Pain intensity (4, 24, and 72 hours post-procedure.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-01
Completion: 2026-07-01
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lviv National Medical University
Collaborators: Vinnitsa National Medical University
Contact Information
Study Contact:
Maksym Barsa, MD, PhD
+380952074098
maxbars@email.ua
Dmytro Dmytriiev, PhD, Dr.med.science, professor
+380674309449
Maksym Barsa
maxbars@email.ua
Communal enterprise "Yuri Semenyuk Rivne Regional Clinical Hospital" of Rivne Regional Council
Interventions
  • Procedure: Cryoablation — Cryoablation and radiofrequency ablation are minimally invasive interventional pain management techniques used in this study to target intercostal nerves involved in pain transmission following thoracic combat-related trauma. Cryoablation achieves analgesia through the localized application of extreme cold, producing a temporary and reversible interruption of nerve conduction while preserving nerve structure. In contrast, radiofrequency ablation uses controlled radiofrequency-generated thermal energy to modulate nerve function and reduce pain transmission. Both interventions are performed percutaneously under image guidance to ensure accurate targeting of the affected intercostal nerves, with the number of treated levels determined by injury pattern and clinical assessment. Each intervention is administered in addition to standard trauma and supportive care, with the aim of reducing acute pain intensity, limiting opioid requirements, and improving functional outcomes such as respirator
  • Procedure: Radiofrequency ablation alone — Radiofrequency ablation is a minimally invasive interventional technique that uses controlled radiofrequency-generated thermal energy to modulate peripheral nerve function and reduce pain transmission. In this study, radiofrequency ablation is applied to intercostal nerves associated with thoracic combat-related trauma using a percutaneous, image-guided approach. Thermal energy is delivered in a controlled manner to achieve nerve modulation while limiting damage to surrounding tissues. This intervention is intended to provide effective acute pain relief, reduce opioid requirements, and improve functional outcomes such as respiratory mechanics in patients with thoracic injuries.
Study Locations (1 sites)
Communal enterprise "Yuri Semenyuk Rivne Regional Clinical Hospital" of Rivne Regional Council, Rivne, Ukraine
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Thoracic trauma from combat-related injuries * VNRS ≥4 for acute thoracic pain * Ability to provide informed consent Exclusion Criteria: * Severe coagulopathy * Infection at intervention site * Allergy to local anesthetics * Inability to perform spirometry
Conditions Depression, Anxiety, Visual Impairment, ...
Phase NA
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to develop and pilot test a therapeutic strategy combining cognitive behavioral therapy (CBT) with mindfulness practices tailored for individuals adjusting to vision loss. The study will begin with focus groups to inform the design of the intervention. Participants will complete brief surveys on their background and experiences with vision loss prior to attending a focus group, and some may be invited to a second session to provide additional feedback before preliminary testing begins. In the pilot phase, participants will attend weekly group therapy sessions using the developed intervention and complete assessments before and after the program, including questions about vision status, demographics, and experiences with vision loss.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Integrated Cognitive Behavioral Therapy (CBT) & Mindfulness Group Intervention for Adjustment to Vision Loss — The intervention will be an 8-week integrated group therapy curriculum combining cognitive behavioral therapy (CBT) with mindfulness practices designed for individuals adjusting to vision loss.

Primary Outcomes

  • Change from Baseline in Mean Adaption to Vision Loss (AVL) Scale Score (Assessed at baseline and following the 8-week intervention period)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-14
Completion: 2027-07-13
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Chicago Lighthouse
Principal Investigators:
  • Chief Research Officer (PRINCIPAL_INVESTIGATOR) - The Chicago Lighthouse
Contact Information
Study Contact:
Senior Research Associate
(312) 447-3254
Research@chicagolighthouse.org
Senior Research Associate
312-447-3254
Research@chicagoligthhouse.org
The Chicago Lighthouse
312-447-3234
The Chicago Lighthouse
Interventions
  • Behavioral: Integrated Cognitive Behavioral Therapy (CBT) & Mindfulness Group Intervention for Adjustment to Vision Loss — The intervention will be an 8-week integrated group therapy curriculum combining cognitive behavioral therapy (CBT) with mindfulness practices designed for individuals adjusting to vision loss.
Study Locations (1 sites)
The Chicago Lighthouse, Chicago, Illinois 60608 United States
Eligibility Criteria
Inclusion Criteria: * Adults who are at least 18 years old * Experiencing varying degrees of vision loss (e.g. mild, moderate, severe) * Willingness to participate in the focus group or pilot testing and provide feedback Exclusion Criteria: * Individuals with severe cognitive impairment affecting participation * Congenital blindness * Recent or current participation in another clinical trial study or medical intervention that may interfere with study results * Documented or self-reported health condition that may interfere with the outcomes of this study. * Deemed unfit to participate in the study by the site investigator * Unwilling and/or unable to participate or provide consent
Conditions Chronic Kidney Diseases, Depression
Phase NA
Enrollment 104
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Investigation of the efficacy of Acceptance and Commitment Therapy (ACT) for the psychological treatment of patients with chronic kidney disease.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: ACT — Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.

Primary Outcomes

  • Change in emotional distress assessed through Hospital Anxiety and Depression Scale (HADS) (Change from Baseline Emotional Distress at 5 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-01
Completion: 2026-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 104 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universidad Europea de Madrid
Collaborators: Fundación Renal Iñigo Alvarez De Toledo, Centro de Enseñanza Superior Cardenal Cisneros
Principal Investigators:
  • Francisco Montesinos, Ph.D. (PRINCIPAL_INVESTIGATOR) - Universidad Europea de Madrid
Contact Information
Study Contact:
Francisco Montesinos, Ph.D.
+34647413773
francisco.montesinos@universidadeuropea.es
Lola Arenas
+34673429833
mdarenas@friat.es
Fundación Renal Iñigo Alvarez de Toledo
Interventions
  • Behavioral: ACT — Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
Study Locations (1 sites)
Fundación Renal Iñigo Alvarez de Toledo, Madrid, 28003 Spain
Eligibility Criteria
Inclusion Criteria: * Patients with chronic kidney disease on haemodialysis * Older than 18 years-old * At least 3 months on haemodialysis * HADS Global Scale Score ≥14 Exclusion Criteria: * Diagnosis of severe or chronic mental disorder, mental retardation and cognitive impairment, or disabling illness. * Antidepressant drugs consume * Insufficient understanding of Spanish. * Patients who are in the Advanced Chronic Kidney Disease Unit * Receiving other psychological treatment
Conditions Major Depressive Disorder
Phase NA
Enrollment 144
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Patients, physicians, and those who fund depression research are keenly interested in depression treatments that do not involve taking medications. One promising candidate treatment is transcranial direct current stimulation (tDCS), a low-cost technique that involves placing electrodes on specific scalp locations and using a 9-volt battery to cause a small amount of electricity to pass through parts of the brain. Depending on the direction of electrical flow, tDCS can make brain cells (neurons) more likely or less likely to generate their own electrical signals. When evaluated as a treatment, tDCS is typically done in daily sessions over a period of two weeks. One of the challenges of tDCS is to work out the best possible positioning of electrodes and direction of electricity flow to gradually cause lasting changes in brain activity in ways that might be expected to improve depression. To address this challenge, the investigators are using MRI to take pictures of the brain during tDCS. This data will help us better understand the short-term effects of tDCS in depression and help us learn how to customize future treatments to cause a lasting beneficial response. Patients with depression between the ages of 20-55 years are eligible to take part in this research. Potential participants will undergo: 1. An assessment to confirm eligibility. This will take place over a secure videoconference call lasting no more than 3 hours. 2. Two in-person study visits lasting 30 min and 2-1/2 hours respectively. In the first visit, the investigators will use the MRI to take a picture of the brain and head structure to determine appropriate locations for placing the tDCS electrodes at the start of the second visit. Following electrode placement, an MRI scan will be performed to take pictures of the brain during tDCS. Depending on the study arm, 1. Participants may receive 'active' or 'sham' tDCS. The 'sham' condition is identical to the 'active' tDCS in every way except that it involves minimal tDCS and is designed to help rule out effects unrelated to the administered tDCS electricity. 2. Participants may also be asked to perform a mental task during MRI.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Single

Interventions / Regimen

  • Device: Left DLPFC tDCS — This intervention involves placing non-invasive scalp-electrodes over the left DLPFC brain region to deliver a mild, tolerable electric current.
  • Device: Right DLPFC tDCS — This intervention involves placing non-invasive scalp-electrodes over the right DLPFC brain region to deliver a mild, tolerable electric current.
  • Behavioral: Cognitive task — Participants will be asked to perform a 2-back working memory mental task alongside administered tDCS

Primary Outcomes

  • Activity changes in the dorso-fronto-limbic brain network (Within the 2.5 hour fMRI session)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-10-20
Completion: 2028-05-01
Eligibility
Age: 20 Years – 55 Years
Sex: ALL
Volunteers: false
Enrollment: 144 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Los Angeles
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Mayank A Jog, PhD (PRINCIPAL_INVESTIGATOR) - University of California, Los Angeles
Contact Information
Study Contact:
Mayank A Jog, PhD
424-288-6483
brainmapping.ucla@gmail.com
Mayank A Jog, PhD
4242886483
brainmapping.ucla@gmail.com
University of California Los Angeles (UCLA)
Interventions
  • Device: Left DLPFC tDCS — This intervention involves placing non-invasive scalp-electrodes over the left DLPFC brain region to deliver a mild, tolerable electric current.
  • Device: Right DLPFC tDCS — This intervention involves placing non-invasive scalp-electrodes over the right DLPFC brain region to deliver a mild, tolerable electric current.
  • Behavioral: Cognitive task — Participants will be asked to perform a 2-back working memory mental task alongside administered tDCS
Study Locations (1 sites)
University of California Los Angeles (UCLA), Los Angeles, California 90095 United States
Eligibility Criteria
Inclusion Criteria: 1. Age between 20 to 55 years, inclusive 2. Gender: all 3. Race/ethnicity: all races and ethnic groups 4. Capacity to provide informed consent 5. Hamilton Rating Scale for Depression score of ≥17 and \<24, with or without symptoms of anxiety. 6. Treatment naïve or on a stable standard antidepressant regimen (including selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MOAIs) or tricyclic's (TCAs)) with no change in treatment 6-weeks prior to and during the tDCS intervention. 7. Work at UCLA or live within 1-hr driving distance of UCLA Exclusion Criteria: 1. Pregnancy 2. Non-English speaking (due to scales administered) 3. Substance Use Disorder within last 12 months 4. Neurological condition associated with brain abnormalities (e.g., traumatic brain injury; recent stroke, tumor) 5. Any contraindication to tDCS (e.g., skin disease or treatment causing irritation) 6. Any condition that would contraindicate scanning (metal implants, claustrophobia or a breathing or movement disorder) 7. Currently receiving any form of psychotherapy 8. Change in antidepressant medication within 6-weeks of starting the trial 9. Severe or treatment resistant depression - HAMD scores \> 24 and a history of a major depressive episode lasting \>2- years or failure to 2 or more antidepressant trials in the current index episode 10. Any neuromodulation therapy (e.g., ECT, rTMS, DBS, VNS or tDCS) within the last 3-months 11. Current or past (within the last 1-month) use of anticonvulsants, lithium, psychostimulant, dexamphetamine 12. Current use of decongestants or other medication previously shown to interfere with cortical excitability 13. Diagnosis: Schizophrenia Axis I disorder, or dementia of any type 14. Bipolar I disorder (due to possible risk of mania and because lithium and anticonvulsants are excluded). 15. On regular benzodiazepine medication that it is not clinically appropriate to discontinue for the 2-week duration of the trial 16. Depression related to serious medical illness (i.e., mood disorder due to general medical condition) 17. Actively suicidal as defined by a score of 4 on item 3 of HAMD

The Post-ICU Pain Study

NCT07180407
Recruiting
Conditions Chronic Pain, Post Intensive Care Unit S...
Phase Not Applicable
Enrollment 800
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

BACKGROUND: ICU survivors may experience serious psychological, physical and cognitive impairments following ICU admission, collectively termed Post Intensive Care Syndrome (PICS). Persistent pain is an underrecognized component of PICS. Previous research has shown that persistent pain is a profound clinical challenge in ICU survivors, however, research demonstrates conflicting results. Furthermore, no studies have examined the prevalence of persistent pain in ICU survivors in a contemporary Danish ICU setting. OBJECTIVES: We aim to examine the clinical trajectory, risk factors, and pathophysiology of persistent pain in ICU survivors in Denmark. DESIGN AND SAMPLE SIZE: The study is designed as a multicenter, prospective, inception cohort study with clinical follow-up. Based on the pre-study sample size calculation, 800 patients will be included. Patients will be contacted by telephone 90 days and 180 days after ICU discharge, and a series of questionnaires regarding pain, sleep quality, affective state and quality of life will be completed. A subgroup of patients will undergo a detailed clinical examination including quantitative sensory testing between 180-365 days after ICU discharge. POPULATION: Patients will be recruited from 4 Danish ICU departments. Inclusion criteria include adult patients (18 years of age), acute admission to the ICU, and an ICU admission of a minimum of 48 hours. OUTCOMES: The primary outcome is the prevalence of pain assessed by the Brief Pain Inventory (BPI) at 90 and 180 days after ICU discharge. Secondary outcomes include additional detailed descriptions of pain and daily activity, sleep quality, affective state, quality of life, treatment- and patient-related risk factors, and biomarkers associated with development of persistent pain. Substudies: \- QST substudy: 80 participants (40 with pain and 40 without pain) recruited from the main cohort will undergo Quantative Somatosensory Testing (QST). The objectives are first, to delineate somatosensory profiles of ICU survivors with and without pain, and second, to examine the presence of neuropathic pain in ICU survivors.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Prevalence of pain (180 day follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-23
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zealand University Hospital
Collaborators: Aalborg University Hospital
Contact Information
Study Contact:
Bennedikte K Madsen, MD
0045
bkom@regionsjaelland.dk
Bodil S Rasmussen, Professor, MD, PhD
0045
Bodil.steen.Rasmussen@rn.dk
Aalborg University Hospital
Bennedikte Madsen, MD
0045
bkom@regionsjaelland.dk
Zealand University Hospital
Interventions
N/A
Study Locations (4 sites)
Aalborg University Hospital, Aalborg, 9000 Denmark
Zealand University Hospital, Køge, 4600 Denmark
Zealand University Hospital, Nykøbing Falster, 4800 Denmark
Zealand University Hospital, Roskilde, 4000 Denmark
Eligibility Criteria
Inclusion Criteria: * Adult ICU patients ≥18 years of age * Acute admission to the ICU * ICU length of stay of at least 48 hours Exclusion Criteria: * Patients transferred from a non-participating ICU * Patients with pre-planned admission to the ICU e.g., following elective surgery * Patients unable to complete questionnaires, including those who are unable to understand or speak Danish, or patients with severe cognitive deficits.
Conditions Mechanical Ventilation Pressure High, Ve...
Phase NA
Enrollment 258
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Research has shown that timely suctioning not only improves survival rates but also enhances the quality of life in ventilator-dependent patients. However, clinical judgment on the optimal timing for suctioning currently relies primarily on physician experience, lacking scientific evidence \[10\]. Airway viscous resistance reflects the frictional resistance encountered by gas flow within the airways and is closely associated with airway patency. When airway secretions increase, viscous resistance undergoes dynamic changes. Therefore, analyzing these dynamic variations in viscous resistance derived from ventilator waveforms to determine the optimal suctioning timing and assess its clinical impact on the progression of pulmonary inflammation holds significant scientific value and offers new insights and methodologies for clinical practice.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Procedure: The dynamics of airway resistance — Monitoring the dynamic changes in airway resistance in patients can be used to reflect the progression of pulmonary inflammation and determine the optimal timing for suctioning.
  • Diagnostic Test: conventional suctioning — The timing for suctioning is determined based on clinical signs such as rhonchi and an elevated peak pressure.

Primary Outcomes

  • The drop in airway viscous resistance before and after sputum suction (the process of sputum aspiration(at most 30 minutes))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-30
Completion: 2029-12-30
Eligibility
Age: 18 Years – 90 Years
Sex: ALL
Volunteers: false
Enrollment: 258 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Affiliated Hospital of Nantong University
Contact Information
Study Contact:
Hong-lei Wu Nursing Department, MS
+8613862749927
wu_honglei@163.com
xuan Qian Nursing Department, MS
+8615162763676
1660694568@qq.com
Yajun Li Director of the Nursing, MS
+8615955232235
liyajun1205@163.com
The First Affiliated Hospital of Bengbu Medical University
Interventions
  • Procedure: The dynamics of airway resistance — Monitoring the dynamic changes in airway resistance in patients can be used to reflect the progression of pulmonary inflammation and determine the optimal timing for suctioning.
  • Diagnostic Test: conventional suctioning — The timing for suctioning is determined based on clinical signs such as rhonchi and an elevated peak pressure.
Study Locations (3 sites)
The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233000 China
Peking Union Medical College Hospital, Beijing, Beijing Municipality 100000 China
the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009 China
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of Acute Respiratory Distress Syndrome (ARDS) * Clinical diagnosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) * Clinical diagnosis of Severe pneumonia Exclusion Criteria: * Clinical diagnosis of multiple organ failure; * Clinical diagnosis of multiple organ bleeding;
Conditions Intrahepatic Cholangiocarcinoma (Icc), N...
Phase PHASE2
Enrollment 81
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, single-arm, exploratory clinical study for adults with locally advanced intrahepatic cholangiocarcinoma (ICC) that may be technically resectable but is difficult to remove directly by surgery. The study will evaluate whether perioperative treatment with Retlirafusp alfa, famitinib malate, and hepatic arterial infusion chemotherapy using gemcitabine and oxaliplatin (HAIC-GEMOX) can help control the tumor before surgery and support further treatment after surgery. Participants who meet the study requirements will receive neoadjuvant treatment before surgery. After surgery, participants will receive adjuvant treatment with Retlirafusp alfa combined with capecitabine or S-1. The study treatment and follow-up will continue until disease progression, unacceptable side effects, death, withdrawal of consent, or other protocol-defined stopping criteria. The main purpose of the study is to evaluate event-free survival. The study will also monitor tumor response, surgery-related outcomes, survival, and safety. Participants will have regular safety visits, blood tests, imaging examinations, and follow-up visits during and after treatment.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Rilvegostomig Alpha — 30 mg/kg, i.v., q3w, Day 1 of each 3-week cycle.
  • Drug: Famitinib malate — 10 mg, orally, once daily.
  • Drug: Gemcitabine & oxaliplatin — hepatic arterial infusion, Day 1 of each 3-week cycle.
  • Drug: Capecitabine — 1250 mg/m², orally twice daily, Days 1-14 of each 3-week cycle, as postoperative adjuvant therapy.
  • Drug: S-1 — 40 mg/m², orally twice daily, Days 1-28 of each 6-week cycle, as postoperative adjuvant therapy.
  • Procedure: hepatic arterial infusion chemotherapy (HAIC) — Hepatic arterial infusion chemotherapy with gemcitabine and oxaliplatin administered on Day 1 of each 3-week cycle.

Primary Outcomes

  • Event-free survival (EFS) (From the start of treatment until the first EFS event, assessed up to 36 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-09-30
Completion: 2029-03-01
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 81 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
Principal Investigators:
  • Feng Cheng, MD (STUDY_DIRECTOR) - The First Affiliated Hospital with Nanjing Medical University
Contact Information
Study Contact:
Professor Chen, MD
+86 13305170695
docchengfeng@njmu.edu.cn
Jianhua Rao Professor Rao, Ph.D.
+86 18262637266
raojh@njmu.edu.cn
Jianhua Rao Professor Rao, Ph.D.
+86 18262637266
raojh@njmu.edu.cn
The First Affiliated Hospital with Nanjing Medical University
Interventions
  • Drug: Rilvegostomig Alpha — 30 mg/kg, i.v., q3w, Day 1 of each 3-week cycle.
  • Drug: Famitinib malate — 10 mg, orally, once daily.
  • Drug: Gemcitabine & oxaliplatin — hepatic arterial infusion, Day 1 of each 3-week cycle.
  • Drug: Capecitabine — 1250 mg/m², orally twice daily, Days 1-14 of each 3-week cycle, as postoperative adjuvant therapy.
  • Drug: S-1 — 40 mg/m², orally twice daily, Days 1-28 of each 6-week cycle, as postoperative adjuvant therapy.
Study Locations (1 sites)
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu 210029 China
Eligibility Criteria
Inclusion Criteria: Participants must meet all of the following criteria: 1. Voluntarily agree to participate in the study and sign the informed consent form. 2. Age 18 to 75 years at the time of signing informed consent, male or female. 3. Histologically and/or cytologically confirmed intrahepatic cholangiocarcinoma. 4. ECOG performance status of 0 to 1. 5. No prior systemic therapy or tumor-related surgery, except biliary drainage. 6. No extrahepatic metastasis. 7. Considered technically resectable by an experienced hepatobiliary surgeon. 8. At least one measurable lesion according to RECIST 1.1. 9. Adequate organ and bone marrow function, as defined by the protocol. 10. Women of childbearing potential must have a negative serum pregnancy test within 7 days before treatment and agree to use effective contraception during the study and for 1 year after the last study treatment. Male participants with partners of childbearing potential must also agree to use effective contraception during the study and for 1 year after the last study treatment. 11. Life expectancy of at least 12 weeks. Exclusion Criteria: Participants meeting any of the following criteria will be excluded: 1. Pathological diagnosis of hepatocellular carcinoma, mixed liver cancer, or other non-cholangiocarcinoma malignant tumor components. 2. Prior systemic therapy or other tumor-related treatment, except biliary drainage. 3. Diagnosis of any other malignancy within 5 years before the first study treatment, except cured localized tumors such as cervical carcinoma in situ, basal cell carcinoma of the skin, or low-grade prostate cancer. 4. Known uncontrolled pulmonary fibrosis, interstitial lung disease, or acute lung disease. 5. Participation in another clinical trial of an investigational drug or device within 4 weeks before the first study treatment. 6. Active hepatitis B or hepatitis C infection. 7. Active autoimmune disease requiring systemic treatment within 2 years before the first
Conditions Age-Related Macular Degeneration, Diabet...
Phase NA
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates hyperspectral retinal imaging as a novel, non-invasive imaging technique to characterise retinal and optic nerve structures in healthy individuals and patients with eye disease. Hyperspectral imaging captures retinal data across multiple wavelengths to generate detailed spectral information that may reveal features not visible with conventional retinal photography. Approximately 1000 participants will undergo multi-modal ophthalmic imaging in Melbourne, Australia, including hyperspectral imaging, OCT, fundus photography, and related tests. The study aims to compare hyperspectral imaging with standard imaging methods and assess its ability to identify retinal biomarkers associated with diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: Hyperspectral camera — Hyperspectral imaging is performed with the Metabolic Hyperspectral Retinal Camera (Optina Diagnostic, Montreal, Canada) and a prototype camera developed by researchers at the Centre for Eye Research Australia (CERA). The Metabolic Hyperspectral Retinal Camera is similar to a typical fundus imager but it incorporates a tunable light source which is able to transmit safe light levels within a wavelength range covering the visible to near infrared with a narrow bandwidth (\< 3nm). This instrument is capable of imaging a 26° field-of-view of retina at 90 wavelengths in less than a second, thus minimizing discomfort and limiting the influence of eye movements. The hyperspectral camera developed by CERA researchers is a non-mydriatic fundus camera that uses light emitting diodes (LEDs) and an optical variable bandpass filter to tune the illumination wavelengths.

Primary Outcomes

  • Diagnostic performance of hyperspectral imaging-derived spectral score for detection of retinal disease (During study visit (baseline data collection); analyses performed after completion of participant recruitment and imaging dataset acquisition)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-01
Completion: 2028-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Center for Eye Research Australia
Contact Information
Study Contact:
Darvy Dang
+61 3 9959 0102
darvy.dang@unimelb.edu.au
Darvy Dang, Masters of Orthoptics
+61 3 9959 0102
darvy.dang@unimelb.edu.au
The Centre for Eye Research Australia
Interventions
  • Device: Hyperspectral camera — Hyperspectral imaging is performed with the Metabolic Hyperspectral Retinal Camera (Optina Diagnostic, Montreal, Canada) and a prototype camera developed by researchers at the Centre for Eye Research Australia (CERA). The Metabolic Hyperspectral Retinal Camera is similar to a typical fundus imager but it incorporates a tunable light source which is able to transmit safe light levels within a wavelength range covering the visible to near infrared with a narrow bandwidth (\< 3nm). This instrument is capable of imaging a 26° field-of-view of retina at 90 wavelengths in less than a second, thus minimizing discomfort and limiting the influence of eye movements. The hyperspectral camera developed by CERA researchers is a non-mydriatic fundus camera that uses light emitting diodes (LEDs) and an optical variable bandpass filter to tune the illumination wavelengths.
Study Locations (1 sites)
The Centre for Eye Research Australia, Melbourne, Victoria 3002 Australia
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years and older * Able to provide informed consent * Willing and able to attend a study visit at the Centre for Eye Research Australia * Participants with diagnosed retinal or optic nerve disease (e.g., diabetic retinopathy, glaucoma, age-related macular degeneration) * Age- and sex-matched healthy control participants without known retinal or optic nerve disease Exclusion Criteria: * Inability to provide informed consent * Ocular conditions preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous haemorrhage) * Known contraindication to pharmacological pupil dilation * History of narrow anterior chamber angle or risk of angle closure glaucoma where dilation is considered unsafe * Any condition that, in the investigator's opinion, would compromise participant safety or image quality
Conditions Hypertension Arterial, 65 Years Older
Phase NA
Enrollment 102
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to assess the effectiveness of an intervention (combination of behavioural recommendations and technical measures) in reducing personal exposure to heat and air pollution and related health effects in older adults with hypertension. The main questions it aims to answer are: * Does the intervention (combination of behavioral recommendations for heat mitigation) reduce personal ambient temperature exposure, measured using a wearable device (iButton)? * Does the intervention (combination of behavioral recommendations for air pollution mitigation and use of indoor air cleaners) reduce indoor exposure to air pollution, measured using indoor air quality sensors (Purple Air)? * Does the intervention (combination of behavioral recommendations for heat mitigation) improve the abnormalities in circadian blood pressure variation experienced by older adults with hypertension, assessed using advanced actigraphy? Researchers will compare measurements between older adults with hypertension carrying out their daily activities in the absence of intervention (control group), those carrying out their daily activities with behavioural recommendations (recommendation intervention group) and those carrying out their daily activities with both behavioural recommendations for heat mitigation and continuous use of indoor air cleaners in their house (heat and air pollution mitigation intervention group) to see if changes in temperature exposure and sleep are different between intervention groups. Participants will: * Wear the wearable devise for continuous personal ambient temperature monitoring (ibutton) daily for a period of three months * Have their core temperature measured using an eCelsius medical capsule in three repeated assessments * Have their blood pressure, oxygen saturation, ECG and heart rate variability measured using 24-hour advanced actigraphy in three repeated assessments * Provide samples of urine and blood biomarkers in three repeated assessments.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Heat intervention — The participants in this group of intervention will receive timely personal alerts for high temperatures and specific recommendations to reduce exposure to heat by changing patterns of time spent and physical activity performed outdoors, regulating indoor temperature using fans and/or air conditioning devices, as well as recommendations for mitigation of heat-related health effects (hydration, body cooling) in written and animated format, through mobile phones, web application and online tools to be developed by the project research team.
  • Behavioral: Heat and air pollution mitigation intervention — The participants in this intervention group will receive alerts and recommendations as in group "Heat intervention" and, in addition, continuously use air cleaners with HEPA filters for removing PM from indoor air in their residences and workplaces

Primary Outcomes

  • Percentage dipping in night-time systolic blood pressure (SBP) (Percentage dipping (Dipping %=([Mean Daytime SBP-Mean Night-time BP]/Mean Daytime SBP)×100) in night-time SBP will be assessed at baseline, middle (after 1 month), and at end of the observation period (after 2 months).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-01
Completion: 2027-07-31
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 102 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Cyprus
Collaborators: FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA, PANCYPRIAN FEDERATION OF LABOUR
Principal Investigators:
  • Panayiotis Yiallouros, Professor (PRINCIPAL_INVESTIGATOR) - University of Cyprus
Contact Information
Study Contact:
Panayiotis Yiallouros, Professor
+35722895212
yiallouros.panayiotis@ucy.ac.cy
Panayiotis Kouis, PhD
+35722895243
kouis.panayiotis@ucy.ac.cy
Panayiotis Kouis, PhD
+35722895243
kouis.panayiotis@ucy.ac.cy
Medical School, University of Cyprus
Interventions
  • Behavioral: Heat intervention — The participants in this group of intervention will receive timely personal alerts for high temperatures and specific recommendations to reduce exposure to heat by changing patterns of time spent and physical activity performed outdoors, regulating indoor temperature using fans and/or air conditioning devices, as well as recommendations for mitigation of heat-related health effects (hydration, body cooling) in written and animated format, through mobile phones, web application and online tools to be developed by the project research team.
  • Behavioral: Heat and air pollution mitigation intervention — The participants in this intervention group will receive alerts and recommendations as in group "Heat intervention" and, in addition, continuously use air cleaners with HEPA filters for removing PM from indoor air in their residences and workplaces
Study Locations (2 sites)
Medical School, University of Cyprus, Nicosia, Cyprus
Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain
Eligibility Criteria
Inclusion Criteria: * Aged ≥65 years * Living in Barcelona (Spain) or Nicosia (Cyprus) metropolitan areas * Have a physician's diagnosis of arterial hypertension * Receive daily anti-hypertensive medication * Clinically stable Exclusion Criteria: * Currently smoking * Presence of any smoking residents in the household * Not residing at the household for at least 5 days a week * Planning to move from the current home within the next two months * No access to Wi-Fi or 4G/5G mobile phone * Severe chronic conditions (congestive heart failure, ischemic heart disease, significant valvular heart disease, diabetes mellitus type 2 (DM2), inflammatory diseases, renal failure, or active cancer) * Illicit drugs abuse * Alcohol abuse * Psychiatric disorders * Severe mental disability that interferes with answering questions or following instructions